ArticleProbiotics and antimicrobial proteins2017
Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity.
Article in Probiotics and antimicrobial proteins, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 57 citations in OpenAlex.
- N-3 highly unsaturated fatty acids combined with pro-biotics or post-biotics synergistically alleviate dyslipidemia in rats exposed to chronic mild stress.Nutrition research and practice · 2025Article
- Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.World journal of hepatology · 2025Review
- Correlation Between Lipid Accumulation Product and Metabolic Dysfunction-Associated Steatotic Liver Disease in Chinese Adults with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Mechanisms of gut microbiota in host fat deposition: metabolites, signaling pathways, and translational applications.Frontiers in microbiology · 2025Review
- Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective.Frontiers in cellular and infection microbiology · 2025Review
- Diagnosing and engineering gut microbiomes.EMBO molecular medicine · 2024Review
- Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity.Current issues in molecular biology · 2024Review
- Probiotic for Pancreatic β-Cell Function in Type 2 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Nonalcoholic Fatty Liver Disease and Omega-3 Fatty Acids: Mechanisms and Clinical Use.Annual review of nutrition · 2023Review
- Yunpi Heluo decoction reduces ectopic deposition of lipids by regulating the SIRT1-FoxO1 autophagy pathway in diabetic rats.Pharmaceutical biology · 2022Article
- Review
- Probiotic Composition and Chondroitin Sulfate Regulate TLR-2/4-Mediated NF-κB Inflammatory Pathway and Cartilage Metabolism in Experimental Osteoarthritis.Probiotics and antimicrobial proteins · 2021Article
- Alleviation of halitosis by use of probiotics and their protective mechanisms in the oral cavity.New microbes and new infections · 2021Review
- Quercetin Ameliorates Gut Microbiota Dysbiosis That Drives Hypothalamic Damage and Hepatic Lipogenesis in Monosodium Glutamate-Induced Abdominal Obesity.Frontiers in nutrition · 2021Article
- Importance of the Microbiota Inhibitory Mechanism on the Warburg Effect in Colorectal Cancer Cells.Journal of gastrointestinal cancer · 2020Review
- New insights on strain-specific impacts of probiotics on insulin resistance: evidence from animal study.Journal of diabetes and metabolic disorders · 2020Article
- Crosstalk between gut microbiota and antidiabetic drug action.World journal of diabetes · 2019Review
- Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.Frontiers of medicine · 2018Review
- Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.Nutrients · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Today probiotics have been suggested as a treatment for the prevention of NAFLD. Omega-3 fatty acid supplementation may have beneficial effects in regulating hepatic lipid metabolism, adipose tissue function and inflammation. The present study was designed to determine whether probiotics plus omega-3 are superior to probiotics alone on the monosodium glutamate (MSG)-induced NAFLD model in rats. We included 60 rats divided into four groups, 15 animals in each. Rats of group I were intact. Newborn rats of groups II-IV were injected with MSG. The III (Symbiter) group received 2.5 ml/kg of multiprobiotic "Symbiter" containing concentrated biomass of 14 probiotic bacteria genera. The IV (Symbiter-Omega) groups received "Symbiter-Omega" combination of probiotic biomass supplemented with flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5 %). In both interventional groups reduction in total NAS score was observed. Supplementation of alive probiotic mixture with omega-3 fatty acids lead to 20 % higher decrease in steatosis score (0.73 ± 0.11 vs 0.93 ± 0.22, p = 0.848) and reduction by 16.6 % of triglycerides content in liver as compared to probiotic alone. Our study demonstrated more pronounced reduction in hepatic steatosis and hepatic lipid accumulation after treatment with combination of alive probiotics and omega-3 as compared to probiotics alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.